22
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Autoimmunity to Ryanodine Receptor and Titin in Myasthenia Gravis is Associated with GM Allotypes

, , &
Pages 111-116 | Received 22 Oct 1996, Accepted 07 Mar 1997, Published online: 07 Jul 2009

References

  • Lindstrom J., Schelton D., Fujii Y. Myasthenia gravis. Adv. Immunol. 1988; 42: 233–284
  • Murphy J., Murphy S. F. Myasthenia gravis in identical twins. Neurology 1986; 36: 78–80
  • Bergoffen J., Zmijewski C. M., Fischbeck K. H. Familial autoimmune myasthenia gravis. Neurology 1994; A: 551–554
  • Degli-Esposti M. A., Andreas A., Christiansen F. T., Schalke B., Albert E., Dawkins R. L. An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes. lmmunogenetics 1992; 35: 355–364
  • Marshall B., Leelayuwat C, Abraham L. J., Pinelli M., Dawkins R. L. Large transcripts and sequence from a polymorphic 170 kb MHC region implicated in susceptibility to autoimmune disease. lmmunogenetics 1994; 39: 15–20
  • Carlsson B., Wallin J., Pirskanen R., Matell G., Smith C. I. E. Different HLA DR-DQ associations in subgroups of idiopathic myasthena gravis. lmmunogenetics 1990; 31: 285–290
  • Spurkland A., Gilhus N. E., Rønningen K. S., Aarli J. A., Vartdal F. Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Antigens 1991; 37: 90–93
  • Grubb R. Advances in human immunoglobulin allotypes. Exp. Clin. Immunogent. 1995; 12: 191–197
  • Oxelius V. A., Carlsson A. M., Hammarstrøm L., Bjør-Kander J., Hanson L. A. Linkage of IgA deficiency to Gm allotypes; the influence of Gm allotypes on IgA-IgG subclass deficiency. Clin. Exp. Immunol 1995; 99: 211–215
  • Goldblatt D., Scadding G. K., Lund V. J., Wade A. M., Turner M. W., Pandey J. P. Association of Gm Allotypes with the antibody response to the outer membrane proteins of a common upper respiratory tract organism, moraxella catarrhalis. J. Immunol 1994; 153: 5316–5320
  • Nakao Y., Sasazuki T. Gm and disease. Handbook of Experimental Immunology, D. M. Weir, L. A. Herzenberg, C. Blackwell. Blackwell, Oxford 1986; 96. 1–96.10
  • Compston A., Kellar-Wood H., Wood N. Multiple sclerosis. Baillieres Clin. Neurol. 1994; 3(2)353–371
  • Dawkins R. Myasthenia gravis. Histocompatibility Testing, P. I. Teraski. UCLA Tissue Typing Laboratory, Los Angeles 1980; 662
  • Nakao Y., Matsumoto H., Miyazaki T., Nishitani H., Ota K., Fujita T., Tsuji K. Gm allotypes in myasthenia gravis. Lancet 1980; I: 677–680
  • SmithGrubb C. I. E.R., Hammarstrom L., Matell G. Gm allotypes in Swedich myasthenia gravis patients. J. Immunogenelics 1983; 10: 1–9
  • Smith C. I. E., Grubb R., Hammarstrom L., Pirska-Nen R. Gm allotypes in Finnish myasthenia gravis patients. Neumlogx 1984; 34: 1604–1605
  • Chiu H. C, de Lange G. G., Willcox N., Vincent A., Ncwsom-Davis J., Hsieh K. H., Hung T. P. Immunoglobulin allotypes in Caucasian and Chinese myasthenia gravis: differences from Japanese paiienls. J. Neurol. Neurosurg. Psychiatry 1988; 51: 214–217
  • Gilhus N. E., Pandeyl J. P., Gaarder P. I., Aarli J. A. Immunoglobulin Allotypes in myasthenia gravis patients with a thymoma. Autoimmunity 1990; 3: 299–305
  • Gautel M., Lakey A., Barlow P. D., Holmes Z., Scales S., Leonard K., Labeit S., Mygland A., Gilhus N. E., Aarli J. A. Titin antibodies in myasthenia gravis: identilication of a major immunogenic region of titin. Neurology 1993; 43: 1581–1585
  • Skeie G. O., Mygland A., Aarli J. A., Gilhus N. E. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 1995; 20: 99–104
  • Mygland A., Tysnes O. B., Matre R., Volpe P., Aarli J. A., Gilhus N. F. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann. Neurol 1992; 32: 589–591
  • Wiebecke D. The incidence of Gm(l,2,3,5) and Inv(1) in the population of the federal republic of Germany. Humangenetik 1973; 18: 175–180
  • Mygland A., Tysnes O. B., Aarli J. A., Flood P. R., Gilhus N. E. Myasthenia gravis patients with a thymoma have antibodies against a high molecular weight protein in sarcoplasmatic reticulum. J. Neuwimmunoi 1992; 37: 1–7
  • Gaarder P. I., Natvig J. B. Distribution of isotypic and allotypic human IgG antigens in non-human primates. J. Immunol 1974; 113: 635–644
  • Schanficld M. S., van Logheim E. Human immunoglobulin allotypes. Handbook of Experimental Immunology, D. M. Weir, L. A. Herzenberg, C. Blackwell. Blackwell, Oxford 1986; 94
  • Guidelines for human gene nomenclature. An international system for human gene nomenclature (ISGN.1987). Cyto-genet. Cell Genet. 1987; 46: 11–28
  • Natvig J. B. Gm(g), a new human gamma-globulin factor determined by a gene behaving as allele of Gm5 in Caucasians. Bibl. Haematol 1968; 29: 294–298
  • Sarvas H., Rautonen N., Sipinen S., Makela O. IgG Subclasses of pneumococcal antibodies-effect on allotype G2m(n). Scand. J. Immunol 1989; 29: 229–237
  • Ambrosino D. M., Schiffman G., Gotschlich E. C, Schur P. H., Rosenberg G. A., DeLange G. G., van Logheim E., Siber G. R. Correlation between G2m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. J. Clin. Invest. 1985; 75: 1935–1942
  • Weiss J. B., Austin R. K., Schanfield M. S., Kag-Noff M. K. Gluten-sensitive eneropathy. Immunoglobulin G heavy-chain (Gm) allotypes and the immune response to wheat gliadin. J. Clin. Invest. 1983; 72: 96–101
  • Legrand L., Rivat-Perran L., Huttin C, Ling N. R., Richardson P. HLA-and Gm-linked genes affecting the degradation rate of antigens (Sheep red blood cells) endocytozed by macrophages. Hum. Immunol. 1982; 4: 1–13
  • Willcox N. Myasthenia gravis. Curr. Opin. Immunol 1993; 5: 910–917
  • Marx A., Osborn M., Tzartos S., Geuder K. I., Schalkc B., Nix W., Kirchner T., Miiller-Hermelink H. K. A striational muscle antigen and myasthenia gravis associated thymomas share an acetylcholine-receptor epitope. Dev. Immunol 1992; 2: 77–84
  • Mygland A., Kuwajima G., Mikoshiba K., Tysnes O. B., Aarli J. A., Gilhus N. E. Thymomas express epitopes shared by the ryanodine receptor. J. Neuroim-munol 1995; 62: 79–83
  • Gilhus N. E., Willcox N., Harcourt G., Nagvekar N., Beeson D., Vincent A., Newsom-Davis J. Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells. J. Neuroimmunol 1995; 56: 65–76
  • Demaine A., Willcox N., Janer M., Welsh K., Newsom-Davis J. Immunoglobulin heavy chain gene associations in myasthenia gravis: new evidence for disease heterogeneity. J. Neurol 1992; 239: 53–56
  • Mygland A., Tysnes O. B., Aarli J. A., Matre R., Gilhus N. E. IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma. J. Autoimmunity 1993; 6: 507–515
  • Morell A., Skvaril F., Steinberg A. G., van Logheim E., Terry W. D. Correlations between the concen trations of the four subclasses of IgG and Gm allotypes in normal human sera. J. Immunol 1972; 108: 195–206
  • Oxelius V. A. Serum IgG and IgG subclass contents in different Gm phenotypes. Scand. J. Immunol 1993; 37: 149–153
  • Pandey J. P., French A. H. GM phenotypes influence the concentrations of the four subclasses of IgG in normal human serum. Hum. Immunology 1996, (In press)
  • Mygland A., Aarli J. A., Matre R., Gilhus N. E. Ryanodine receptor antibodies related to severity of thymoma-associated myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 1994; 57: 843–846
  • Skeie G. O., Bartoccioni E., Evoli A., Aarli J. A., Gilhus N. E. Ryanodine receptor antibodies are associated with severe myasthenia gravis. Eur. J. Neurol 1996; 3: 136–140
  • Mathiesen T., Persson M. A. A., Sundquist V. A., Wahren B. Neutralization capacity and antibody dependent cell mediated cytotoxity of separated IgG subclasses 1,3 and 4 against herpes simplex virus. Clin. Exp. Immunol 1988; 72: 211–215
  • Rodgaard A., Nielsen F. C, Djurup R., Somnier F., Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin. Exp. Immunol 1987; 67: 82–88

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.